The abstract is read at the publisher; the summary is JClub's.
Loss of Mtm1 in XLMTM mice fed purified ingredient diets precipitates cholestatic liver disease, with elevated plasma transaminases, altered bile acids, and cholestasis histology.
- Why it matters: AAV-mediated liver injury is a key off-target toxicity, yet murine models poorly predict it, leaving mechanisms behind fatal patient liver events unclear.
- What they did: In XLMTM mouse models, Mtm1 knockout or liver-specific deletion was used to test a multihit interaction with postweaning diet, and diet-sensitized mice were treated with AAV8-driven gene therapy.
- The result: AAV8 gene therapy increased cholestasis susceptibility in global KO mice and induced liver injury in wild-type mice, while lipid nanoparticle MTM1 gene replacement prevented key histopathological abnormalities.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.